Mechanism of action The substance blocks NS5A, a protein necessary for hepatitis C virus replication and assembly. Pharmacokinetics<unk>  reaches peak plasma concentrations three hours after oral intake together with grazoprevir (variation between patients: three to six hours). In hepatitis C patients, steady state concentrations are found after about six days. Plasma protein binding is over 99.9%, mainly to albumin and alpha-1-acid glycoprotein. Part of the substance is oxidised in the liver, largely by the enzyme CYP3A4. The biological half-life is 24 hours on average. Over 90% are excreted via the faeces, and less than 1% via the urine.
Elbasvir
Odalasvir
Remdesivir
Ombitasvir
Maribavir
Fostemsavir
Velpatasvir
Ledipasvir